Alkermes Plc

ALKS remains in Stage 2 advancing within a long-term uptrend, preserving a medium-term bullish bias despite a recent pullback into key EMA support. Price is retracing into the 9/20 EMA zone on lighter volume with no exhaustion signals, offering no immediate entry trigger. We defer execution and await acceptance at the EMAs for a better entry opportunity.

• ↑Q1 2026 net sales $338.1M (+38% YoY) driven by proprietary products
• ↑Interim alixorexon narcolepsy trial shows sustained wakefulness improvements
• ↓Overvalued ~64% above GF Value; negative earnings yield and low profitability